|
2. ETIOLOGIE
|
|
|
|
|
3.3 PRÉVENTION - VACCINS
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
Carl Heneghan and Jeffrey Aronson: Interpreting lung cancer screening studies [BMJ]
|
|
|
|
|
|
Reductions in lung cancer mortality rates and a shift to earlier detection of disease create considerable pressures to implement lung cancer screening. We should, however, pause before considering implementation, because of the lack of effect on all-cause mortality in NELSON, the problems of false positives and overdiagnosis, potential biases, the substantial resources required, and the economic costs.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
New chemo combo shows promise versus pancreatic cancer [Cornell]
|
|
|
|
|
|
The study, published Feb. 27 in Cancer Cell, found that palbociclib may stop pancreatic cancer cells from repairing DNA damage caused by chemotherapy; that DNA damage is what causes the cancer cells to die. This result suggests that chemotherapy drugs used for pancreatic cancer, such as paclitaxel, should be given first, followed by palbociclib.
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA,...
|
|
|
|
5.4.1 TRAITEMENTS - ECONOMIE - NICE
|
|
|
|
|
|
6.3 ASSOCIATIONS/FONDATIONS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|
Two Tribes [In The Pipeline]
|
|
|
|
|
|
I remember hearing, years back, a prediction that over time every medicinal chemist would just naturally have computational chemistry as part of their tool kit, and that distinction between the tribes would disappear. Hasn’t happened.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|